Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow; iron oxide red - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - hypertension. data have not been provided to support the use of this drug in renovascular disease. symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone - dilatrend is indicated for the treatment for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow; iron oxide red - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; crospovidone; microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii -iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii -iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; povidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).